Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Stephens in a note issued to investors on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Stephens‘s target price would indicate a potential upside of 141.98% from the stock’s previous close.
Several other brokerages have also commented on IMDX. Weiss Ratings reissued a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a report on Monday, September 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Insight Molecular Diagnostics in a research note on Tuesday, August 18th. Finally, Wall Street Zen lowered Insight Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.50.
Read Our Latest Stock Report on IMDX
Insight Molecular Diagnostics Stock Up 4.0%
Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $0.56 million for the quarter.
Insiders Place Their Bets
In other news, major shareholder Broadwood Partners, L.P. acquired 3,428,571 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were bought at an average price of $1.75 per share, for a total transaction of $5,999,999.25. Following the acquisition, the insider owned 16,113,455 shares of the company’s stock, valued at approximately $28,198,546.25. This trade represents a 27.03% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.21% of the company’s stock.
About Insight Molecular Diagnostics
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Further Reading
- Five stocks we like better than Insight Molecular Diagnostics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
